Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high propensity for local invasion and metastasis. Although combining surgery with chemotherapy has immensely improved the outcomes of osteosarcoma patients, the prognosis of metastatic or recurrent osteosarcomas is still...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer letters Ročník 500; s. 1 - 10
Hlavní autori: Chen, Chenglong, Xie, Lu, Ren, Tingting, Huang, Yi, Xu, Jie, Guo, Wei
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Ireland Elsevier B.V 01.03.2021
Elsevier Limited
Predmet:
Antigens
Bone cancer
Cancer immunotherapy
Cancer therapies
Chemotherapy
Clinical trials
Cytokines
Cytotoxicity
Dendritic cells
Fibroblasts
Immune response
Immune system
Immunotherapy
Listeria
Lymphocytes
Malignancy
Medical prognosis
Metastases
Metastasis
Osteosarcoma
Patients
PD-1
PD-L1
Sarcoma
Surgery
Tumor immune microenvironment
Tumors
Vaccines
Vascular endothelial growth factor
PD-L1
Tumor immune microenvironment
Cancer immunotherapy
Osteosarcoma
PD-1
ISSN:0304-3835, 1872-7980, 1872-7980
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high propensity for local invasion and metastasis. Although combining surgery with chemotherapy has immensely improved the outcomes of osteosarcoma patients, the prognosis of metastatic or recurrent osteosarcomas is still unsatisfactory. Immunotherapy has proven to be a promising therapeutic strategy against human malignancies and improved understanding of the immune response to OS, and biomarker development has increased the number of patients who benefit from immunotherapies in recent years. Here, we review recent advances in immunotherapy in osteosarcoma and discuss the mechanisms and status of immunotherapies in both preclinical and clinical trials as well as future therapies on the horizon. These advances may pave the way for novel treatments requisite for patients with osteosarcoma in need of new therapies. •Immune response affects osteosarcoma both locally and systemically.•There are many immune-based basic studies and clinical trials ongoing, but immunotherapy is not that effective on osteosarcoma.•Despite the potential of immunotherapy in osteosarcoma, some challenges remain, and more attention should be paid to other immune cells but not just T cells in TME.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0304-3835
1872-7980
1872-7980
DOI:10.1016/j.canlet.2020.12.024